Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14984029 | 0.79 | LMNA (0.38) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL26501077 | 0.78 | LMNA (0.41) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL1191595 | 0.78 | LMNA (0.41) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL21453077 | 0.76 | MEN1 (0.42) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL804669 | 0.76 | MEN1 (0.42) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL19865075 | 0.75 | LMNA (0.35) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL6285964 | 0.75 | MEN1 (0.35) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL788610 | 0.74 | LMNA (0.38) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL18684799 | 0.72 | LMNA (0.36) | LMNAMEN1CYP3A4ALOX15KMT2A | |
| SCHEMBL9908446 | 0.72 | MEN1 (0.39) | LMNAMEN1CYP3A4ALOX15KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10780092-B2 | Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators | MERCK SHARP & DOHME CORP. (US) | 2020-09-22 | — | — | US | disclosed |
| US-20190307753-A1 | FUSED PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE STIMULATORS | MERCK SHARP & DOHME CORP. (US) | 2019-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190307753-A1 | FUSED PYRAZINE DERIVATIVES USEFUL AS SOLUBLE GUANYLATE CYCLASE STIMULATORS | PDE2A, PDE3A, PDE5A | LMNA 1822/4885MEN1 2639/4885CYP3A4 1090/4885 |
| US-10780092-B2 | Fused pyrazine derivatives useful as soluble guanylate cyclase stimulators | PDE2A, PDE3A, PDE5A | LMNA 1817/4885MEN1 2650/4885CYP3A4 1158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.